ademaglitazone

Ademaglitazone (ADM) is a novel indole-thiazolidinedione (TZD) hybrid designed as a next-generation insulin-sensitizer for the treatment of "diabesity"—the coexistence of obesity and type 2 diabetes. It acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist with enhanced ligand-receptor stability compared to traditional TZDs like rosiglitazone. Preclinical studies indicate that ademaglitazone improves whole-body insulin sensitivity and enhances GLUT4 translocation in insulin-responsive tissues without promoting significant adipogenesis or body-weight gain. Furthermore, the compound exhibits neuroprotective properties by reducing brain tau hyperphosphorylation, suggesting potential benefits against neurodegenerative complications associated with systemic insulin resistance.